Post Pci Thrombosis Prevention Therapeutics
1. Effient patent expiration
Treatment: Treatment or prophylaxis of thrombosis or embolisms; Use of prasugrel and aspirin in patients requiring the reduction of thrombotic cardiovascular events
EFFIENT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6693115 | COSETTE | Acid addition salts of hydropyridine derivatives |
Jul, 2021
(4 years ago) | |
| US8404703 | COSETTE | Medicinal compositions containing aspirin |
Mar, 2022
(3 years ago) | |
| US8569325 | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jan, 2023
(3 years ago) | |
| US5288726 | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Apr, 2017
(8 years ago) | |
|
US5288726 (Pediatric) | COSETTE | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
Oct, 2017
(8 years ago) | |
|
US8569325 (Pediatric) | COSETTE | Method of treatment with coadministration of aspirin and prasugrel |
Jul, 2023
(2 years ago) | |
|
US8404703 (Pediatric) | COSETTE | Medicinal compositions containing aspirin |
Jul, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2014 |
| M(M-182) | Jul 12, 2019 |
| Pediatric Exclusivity(PED) | Jan 12, 2020 |
Drugs and Companies using PRASUGREL HYDROCHLORIDE ingredient
NCE-1 date: 12 January, 2019
Market Authorisation Date: 10 July, 2009
Dosage: TABLET
How can I launch a generic of EFFIENT before it's drug patent expiration?
More Information on Dosage
EFFIENT family patents
